Properties (52)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
Celyad_Oncology
|
| gptkbp:advertising |
global expansion
|
| gptkbp:budget |
annual report
|
| gptkbp:businessModel |
research and development
licensing agreements |
| gptkbp:CEO |
Christian_Homsy
|
| gptkbp:clinicalTrials |
hospitals
Phase 1 Phase 2 patient response solid tumors hematological malignancies published studies CYAD-01 CYAD-02 |
| gptkbp:collaborations |
academic institutions
biotech companies |
| gptkbp:focus |
cell therapy
|
| gptkbp:founded |
2007
|
| gptkbp:founder |
Christian_Homsy
|
| gptkbp:funding |
grants
|
| gptkbp:headquarters |
Mont-Saint-Guibert,_Belgium
|
| https://www.w3.org/2000/01/rdf-schema#label |
Celyad
|
| gptkbp:investmentFocus |
Venture capital
institutional investors biopharmaceuticals shareholder meetings |
| gptkbp:leadership |
scientific advisory board
|
| gptkbp:market |
gptkb:Asia
gptkb:North_America Europe cell-based therapies |
| gptkbp:partnerships |
Novartis
pharmaceutical companies |
| gptkbp:patentCitation |
CAR T technology
|
| gptkbp:platforms |
cell engineering
|
| gptkbp:products |
NKG2D CAR T-cell therapy
|
| gptkbp:publications |
peer-reviewed journals
|
| gptkbp:regulatoryCompliance |
gptkb:FDA
EMA clinical trial applications |
| gptkbp:research |
clinical trials
|
| gptkbp:research_areas |
oncology
personalized medicine immunotherapy |
| gptkbp:stockExchange |
gptkb:Euronext_Brussels
CYAD |
| gptkbp:technology |
CAR T-cell therapy
|
| gptkbp:tributaryOf |
NKG2D CAR T
TCR_T-cell_therapy |
| gptkbp:website |
www.celyad.com
|